 |
|
|
| |
Population Pharmacokinetics of Cabotegravir in Healthy Adult Subjects and HIV-1 Infected Patients Following Administration of Oral Tablet and Long-Acting Intramuscular Injection
|
| |
| |
Reported by Jules Levin
IAC - 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands
Kelong Han1, Parul Patel2, Mark Baker3, David Margolis2, William Spreen2, Susan Ford4
1GlaxoSmithKline, Upper Providence, PA, USA; 2ViiV Healthcare, Research Triangle Park, NC, USA; 3ViiV Healthcare, Nyon, Switzerland; 4GlaxoSmithKline, Research Triangle Park, NC, USA
Adherence to Long-Acting CAB and RPV Injections Through 96 Weeks of Maintenance Therapy in LATTE-2 / Good adherence to injected cabotegravir and rilpivirine in 230 LATTE-2 participants - (07/31/18)
Patient Satisfaction, Tolerability and Acceptability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting Therapy in HIV-1-Infected Adults: LATTE-2 Week 96 Results (07/27/18)
Durable Suppression 2 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies (07/27/18)
Non-Inferior Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) vs DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in Antiretroviral Treatment-Naive Adults With HIV-1 Infection-Week 48 Results From the GEMINI Studies - (07/25/18)
Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093 (07/27/18)
|
| |
|
|
|
|
|
